Extended indication Extension of indication to include, in combination with a renin-angiotensin system (RAS) inhibitor,
Therapeutic value Possible added value
Total cost 14,933,088.00
Registration phase Registration application pending

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information